Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose Ranging Study of Albiglutide in Japanese Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01098461
First received: February 12, 2010
Last updated: May 29, 2014
Last verified: April 2014

February 12, 2010
May 29, 2014
April 2010
May 2011   (final data collection date for primary outcome measure)
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 [ Time Frame: Baseline and Week 16 ] [ Designated as safety issue: No ]
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the value at Week 16 minus the value at Baseline. Based on Analysis of Covariance (ANCOVA): Change = treatment + Baseline HbA1c + prior therapy. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Change from baseline in HbA1c [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01098461 on ClinicalTrials.gov Archive Site
  • Change From Baseline in HbA1c at Weeks 4, 8, 12, and 16 [ Time Frame: Baseline; Week 4, Week 8, Week 12, and Week 16 ] [ Designated as safety issue: No ]
    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the value at Week 16 minus the value at Baseline. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
  • Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 8, 12, and 16 [ Time Frame: Baseline; Week 4, Week 8, Week 12, and Week 16 ] [ Designated as safety issue: No ]
    The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
  • Change From Baseline in Body Weight at Week 4, 8, 12, and 16 [ Time Frame: Baseline; Week 4, Week 8, Week 12, and Week 16 ] [ Designated as safety issue: No ]
    The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values.
  • Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5% and <7% at Weeks 4, 8, 12, and 16 [ Time Frame: Week 4, Week 8, Week 12, and Week 16 ] [ Designated as safety issue: No ]
    The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5% and <7%) were assessed.
  • Mean Clearance of Albiglutide [ Time Frame: Weeks 0, 1, 4, 5, 8, 12, 13, 16, 20, and 24 ] [ Designated as safety issue: No ]
    Clearance is defined as the volume of plasma cleared of albiglutide per unit time. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 1, 4, 5, 8, 12, and 13) and on the day of the clinic visit at Weeks 16, 20, and 24. At Weeks 0, 1, 4, 8, and 12, pharmacokinetic (PK) samples were collected immediately prior to dosing if a dose was scheduled for that week. At Weeks 16, 20, and 24, PK samples were collected at any time during the visit. The Week 5 post-dose PK sampling was performed any time between Weeks 4 and 6, within 2 to 5 days after administration of a dose; Week 13 post-dose PK sampling was performed any time between Weeks 12 and 14, within 2 to 5 days after administration of a dose of study medication. Modeled population PK data are presented; data were analyzed using a non-linear mixed effect modeling approach. A one-compartment PK model with first-order absorption and elimination processes was selected to describe GSK716155 PK.
  • Mean Volume of Distribution of Albiglutide [ Time Frame: Weeks 0, 1, 4, 5, 8, 12, 13, 16, 20, and 24 ] [ Designated as safety issue: No ]
    Volume of distribution is defined as the apparent volume in which albiglutide is distributed. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 1, 4, 5, 8, 12, and 13) and on the day of the clinic visit at Weeks 16, 20, and 24. At Weeks 0, 1, 4, 8, and 12, PK samples were collected immediately prior to dosing if a dose was scheduled for that week. At Weeks 16, 20, and 24, PK samples were collected at any time during the visit. The Week 5 post-dose PK sampling was performed any time between Weeks 4 and 6, within 2 to 5 days after administration of a dose; Week 13 post-dose PK sampling was performed any time between Weeks 12 and 14, within 2 to 5 days after administration of a dose of study medication. Modeled population PK data are presented; data were analyzed using a non-linear mixed effect modeling approach. A one-compartment PK model with first-order absorption and elimination processes was selected to describe GSK716155 PK.
  • Mean Absorption Rate of Albiglutide [ Time Frame: Weeks 0, 1, 4, 5, 8, 12, 13, 16, 20, and 24 ] [ Designated as safety issue: No ]
    Absorption rate is defined as the rate at which albiglutide enters the blood circulation. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 1, 4, 5, 8, 12, and 13) and on the day of the clinic visit at Weeks 16, 20, and 24. At Weeks 0, 1, 4, 8, and 12, PK samples were collected immediately prior to dosing if a dose was scheduled for that week. At Weeks 16, 20, and 24, PK samples were collected at any time during the visit. The Week 5 post-dose PK sampling was performed any time between Weeks 4 and 6, within 2 to 5 days after administration of a dose; Week 13 post-dose PK sampling was performed any time between Weeks 12 and 14, within 2 to 5 days after administration of a dose of study medication. Modeled population PK data are presented; data were analyzed using a non-linear mixed effect modeling approach. A one-compartment PK model with first-order absorption and elimination processes was selected to describe GSK716155 PK.
  • Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG [ Time Frame: Weeks 0, 1, 4, 5, 8, 12, 13, 16, 20, and 24 ] [ Designated as safety issue: No ]
    EC50 is defined as the concentration of albiglutide that give a half-maximal HbA1c and FPG response. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 1, 4, 5, 8, 12, and 13) and on the day of the clinic visit at Weeks 16, 20, and 24. At Weeks 0, 1, 4, 8, and 12, PK samples were collected immediately prior to dosing if a dose was scheduled for that week. At Weeks 16, 20, and 24, PK samples were collected at any time during the visit. The Week 5 post-dose PK sampling was performed any time between Weeks 4 and 6, within 2 to 5 days after administration of a dose; Week 13 post-dose PK sampling was performed any time between Weeks 12 and 14, within 2 to 5 days after administration of a dose of study medication. EC50 estimates used PK data as well as HbA1c and FPG efficacy data. EC50 was estimated from an inhibitory Emax (maximal possible effect of albiglutide) model.
  • Change from baseline in HbA1c over time [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in Fasting Plasma Glucose (FPG) over time [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in body weight over time [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Proportion of subjects who achieve HbA1c treatment goal [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetic levels of albiglutide [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Dose Ranging Study of Albiglutide in Japanese Subjects
A Dose Finding Study of GSK716155 Versus Placebo in the Treatment of Type 2 Diabetes Mellitus

This is a randomized, double-blind, placebo-controlled, multicenter, 4-parallel-group, dose ranging study evaluating the dose response, efficacy and safety of subcutaneously injected GSK716155 (albiglutide) in Japanese subjects with type 2 diabetes mellitus.

This is a Phase IIb, randomized, double-blind, placebo-controlled, multicenter, 4-parallel-group, dose ranging, superiority study evaluating the dose response, efficacy and safety of weekly and every other week subcutaneously injected GSK716155 (albiglutide) in subjects with type 2 diabetes mellitus.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Biological: albiglutide
    subcutaneous injection of albiglutide
    Other Names:
    • placebo
    • albiglutide 30mg weekly
    • albiglutide 15mg weekly
    • albiglutide 30mg every other week
  • Biological: placebo
    subcutaneous injection of placebo to match albiglutide
  • Active Comparator: albiglutide 15mg weekly
    once weekly subcutaneous injection of albiglutide 15mg
    Intervention: Biological: albiglutide
  • Active Comparator: albiglutide 30mg weekly
    once weekly subcutaneous injection of albiglutide 30mg
    Intervention: Biological: albiglutide
  • Active Comparator: albiglutide 30mg every other week
    subcutaneous injection of 30mg albiglutide every other week
    Intervention: Biological: albiglutide
  • Placebo Comparator: placebo
    once weekly subcutaneous injection of placebo to match albiglutide
    Intervention: Biological: placebo
Seino Y, Inagaki N, Miyahara H, Okuda I, Bush M, Ye J, Holland MC, Johnson S, Lewis E, Nakajima H. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014 Jun;30(6):1095-106. doi: 10.1185/03007995.2014.896327. Epub 2014 Mar 11.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
215
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject with a historical diagnosis of type 2 diabetes mellitus who is currently treated with diet and exercise only or one OAD
  • BMI ≥18 kg/m2 and <35 kg/m2 at Screening
  • HbA1c between 7.0% and 10.0%, inclusive
  • Fasting C-peptide ≥0.8 ng/mL (≥0.26 nmol/L)
  • Female subjects of childbearing potential must be practicing adequate contraception .
  • Able and willing to monitor his/her own blood glucose concentrations with a home glucose monitor.
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Diagnosis of type 1 diabetes mellitus
  • Uncorrected thyroid dysfunction
  • Previous use of insulin within one month prior to screening, or more than seven total days of insulin treatment within three months prior to screening
  • Clinically significantly cardiovascular and/or cerebrovascular disease including, but not limited to the following:

    • Previous history of stroke or transient ischemic attack
    • Active, unstable coronary heart disease within the past six months before Screening
    • Documented myocardial infarction within one year before Screening
    • Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within one year before Screening
    • Unstable angina
    • Clinically significant arrhythmia or valvular heart disease
    • Current heart failure NYHA class II to IV
    • Resting systolic pressure >160 mm Hg or diastolic pressure >95 mm Hg at Screening
    • ECG criteria at Screening
  • Heart rate: <40 and >110 bpm
  • PR interval: <120 and > 210 msec
  • QRS interval: <70 and >120 msec
  • QTc interval (Bazett): >450 msec or >480 msec with bundle branch block
  • Fasting triglyceride level >400 mg/dL at Screening
  • AST or ALT >2xULN, ALP and bilirubin >1.5xULN (except known Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin <35% of total bilirubin)
  • If female, is currently lactating, within 6 weeks post-partum, pregnant, or actively trying to become pregnant
  • Has significant renal disease as manifested by one or more of the following:

    • Creatinine clearance at screening <60 mL/min (calculated by Cockcroft-Gault formula) at Screening
    • Known loss of a kidney either by surgical ablation, injury or disease level
  • A hemoglobinopathy that may affect determination of HbA1c level
  • History of treated diabetic gastroparesis
  • History of significant gastrointestinal surgery, including gastric bypass and banding, or surgeries thought to significantly affect upper gastrointestinal function
  • Current ongoing symptomatic biliary disease or history of acute/chronic pancreatitis.
  • Lipase and amylase at Screening > ULN
  • Severe diabetic neuropathy, preproliferative retinopathy or proliferative retinopathy, history of ketoacidosis or hyperosmolar coma
  • History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 3 years before Screening. (A history of treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is allowed)
  • Acute or chronic history of liver disease, positive hepatitis B surface antigen (HBsAg) or positive hepatitis C testing at Screening
  • Current and history of alcohol or substance abuse
  • Clinically significant anaemia or any other abnormal haematological profile that is considered by the investigator to be clinically significant
  • Prior use of a GLP-1 analog
  • Known allergy to any formulation excipients, or Baker's yeast, or history of drug, or other allergy which, in the opinion of the responsible study physician, contradicts participation
  • History of or family history of medullary carcinoma of the thyroid.
  • History of or family history of multiple endocrine neoplasia type 2
  • Receipt of any investigational drug within the 12 weeks before Screening
Both
20 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01098461
110932
Yes
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP